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Purpose: To assess the levels of inflammatory and angiogenic cytokines in undiluted vitreous 
from treatment-naïve patients with macular edema secondary to nonischemic branch retinal 
vein occlusion (BRVO), with flow cytometric bead array (CBA) and to correlate the results with 
subjective and multiple spectral-domain optical coherence tomography (SD-OCT) parameters.
Methods: A total of 43 eyes from 43 patients (mean age 69.7 years, 23 male) were divided into 
groups of new, “fresh” (n = 28; mean duration after onset 4.1 months) and older BRVO (n = 15; 
11.6 months). Because of macular edema, these patients underwent an intravitreal therapy 
combining a single-site 23 g core vitrectomy with bevacizumab and dexamethasone. Undiluted 
vitreous was then analyzed for interleukin-6 (IL-6), monocyte chemoattractant protein-1 
(MCP-1), and vascular endothelial growth factor isoform A (VEGF-A) levels with CBA and 
correlated with visual acuity (VA), clinical parameters of BRVO (type and perfusion status), and 
morphologic parameters, such as central macular thickness, central retinal thickness, thickness 
of the neurosensory retina, thickness of the serous retinal detachment, and the disruption of the 
ellipsoid line (photoreceptor inner and outer segments) and the external limiting membrane, as 
measured with SD-OCT. Twenty-eight undiluted vitreous samples from patients with idiopathic, 
nonuveitis vitreous floaters served as the controls.
Results: The mean IL-6 was 23.2 pg/mL (standard deviation, ±48.8), MCP-1 was 602.6 (±490.3), 
and VEGF-A was 161.8 (±314.3), and this was higher than in the control group, which had a mean 
IL-6 of 6.2 ± 3.4 pg/mL (P = 0.17), MCP-1 of 253.2 ± 73.5 (P , 0.0000001), and VEGF-A of 
7.0 ± 4.9 (P , 0.003). In all BRVO samples, IL-6 correlated positively with MCP-1 and VEGF-A 
(correlation coefficient r = 0.79 and r = 0.46, respectively). VEGF-A was the only cytokine to 
correlate significantly with SD-OCT parameters (thickness of the neurosensory retina r = 0.31; 
disruption of the ellipsoid line r = 0.33). In the older BRVO group, there was a positive correlation 
between cytokines (IL-6 with MCP-1, r = 0.77; Il-6 with VEGF-A, r = 0.68; MCP-1 and VEGF-A, 
r = 0.68), whereas only IL-6 correlated with MCP-1 in the fresh group (r = 0.8).
Conclusion: The inflammatory markers and VEGF-A were elevated in the vitreous fluid of 
patients with BRVO, and these correlated with one another. VEGF-A was more often correlated 
with the morphologic changes assessed by SD-OCT, whereas the inflammatory markers had no 
significant influence on SD-OCT changes.
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Introduction
Today, we can assess patients with branch retinal vein occlusion (BRVO) not only for 
the assessment of changes in central macular thickness (CMT), but also, to conduct 
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a detailed analysis of the neurosensory retinal layers. The 
prognosis for visual acuity (VA) can be based upon the 
integrity of the ellipsoid line (EL) (photoreceptor inner and 
outer segments) and the external limiting membrane (ELM), 
which are important landmarks for good VA rehabilitation.1 
The development of subfoveal serous detachment seems to be 
a potential negative clinical indicator.2,3 In terms of reducing 
the need for frequent intravitreal reinjections, careful 
spectral-domain optical coherence tomography (SD-OCT) 
analysis also allows for flexible anti-vascular endothelial 
growth factor (VEGF) treatment, which has demonstrated 
significant functional and anatomic changes.4,5
Macular edema (ME) secondary to BRVO occurs 
after multifactorial pathophysiologic changes that affect 
intraocular cytokine levels. Cytokines mediate between 
endothelial cells and inflammatory cells, which themselves 
interact with cytokine expression.6,7 The prolonged contact 
of endothelial cells with proinflammatory cytokines might 
promote more thrombosis, on top of the initial venous 
occlusion. Upregulated VEGF is a known chemoattractant 
cytokine for macrophages and leukocytes and thus plays 
an important role in the pathophysiologic imbalance 
of BRVO.8
Funk et al5 demonstrated that anti-VEGF monotherapy has 
an impact on the expression of VEGF and on inflammatory 
markers, including interleukin-6 (IL-6) and monocyte 
chemoattractant protein 1 (MCP-1), in anterior chamber taps.5 
IL-6 is a major promoter of most acute-phase proteins. It 
mediates the change from acute to chronic inflammation and 
thus combines the inflammatory process with angiogenesis.9 
In central retinal vein occlusion (CRVO), Noma et al10 was 
able to demonstrate that the severity of ME is correlated with 
cytokine imbalance.
Using a combination therapy that involved a core 
vitrectomy, we were able to correlate cytokine levels 
from undiluted vitreous (before drug application) with 
the abovementioned detailed intraretinal layer changes 
assessed preoperatively with SD-OCT.11 In this study, 
we aimed to achieve a better understanding of the BRVO 
pathophysiology and of the predictive value of SD-OCT 
examinations.
Methods
This study was conducted after local institutional review 
board (IRB) approval. Following the protocol of the sixth 
revision of the Declaration of Helsinki, each participating 
patient consented to the study.
Patients were included in the study if they had a BRVO-
associated clinically significant ME (CSME) involving the 
fovea but a macular thickness of not more than 1000 µm, 
which led to a VA of not worse than 2.0 logarithm of the 
minimum angle of resolution (logMAR). Excluded patients 
were patients with BRVO-associated complications, such as 
iris rubeosis or neovascularization. We additionally excluded 
patients with a history of previous intravitreal drug injections 
or surgery.
The Early Treatment Diabetic Retinopathy Study 
(ETDRS) best-corrected VA (BCVA) was assessed at 
5 m, with stopping at three out of five optotypes, and was 
expressed as the logMAR.
SD-OCT (3D OCT-2000; Topcon Corp, Tokyo, Japan) 
was used, acquiring a scan depth of 2.3 mm with a horizontal 
resolution of 20 µm and a longitudinal resolution of 5–6 µm, 
at an amplitude modulation scan (A-scan) speed of 27.000 A 
scans/second.
Consecutive sections, and vertical and horizontal scans 
within the macular region were obtained by a well-trained 
OCT-certified (Vienna Reading Center, Vienna, Austria) 
technician. Using OCT images, a standardized reading 
protocol was performed on the OCT scans, with a quality 
score over 16 dB, including the following six measurements 
(Figure 1):
1.  CMT, calculated as the distance of the inner limiting 
membrane to the basal membrane of the retinal pigment 
epithelium, including all the compartments in between
2.  Total retinal thickness (TRT), defined as the biggest 
distance of the inner limiting membrane to the basal 
membrane of the RPE, within the three-dimensional (3D) 
scan field (127 A-scans)
3.  The thickness of the neurosensory retina (TNeuro)
4.  The subfoveal serous retinal thickness (SRT)
5.  The disruption of the inner and outer photoreceptor 
segments (dEL)
6.  The disruption of the external limiting membrane 
(dELM), at the foveal region.
These measurements were reviewed, with a caliper that 
was built into the software of the OCT machine, by two retina 
specialists (MK/FK) who were blinded to the VA results 
and the results of the cytokine evaluation. The intergrader 
reliability (κ) was assessed with a κ-value of 0.88 to 0.95. 
Additionally, the A-scans were evaluated for the occurrence 
of intraretinal cysts or hyper-reflective spots. To exclude false 
positive findings of dEL or of dELM sections due to overlying 
cystic edema or intraretinal bleeding, the A-scans were 
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scrolled through the macular region. Ischemic retinopathy 
was declared with .ten disc areas of nonperfusion by 
fluorescein angiography, using the OIS WinStation 11 K™ 
(Ophthalmic Imaging Systems, Inc, Sacramento, CA, 
USA). In cases of an early, “fresh” BRVO with extensive 
hemorrhage blocking the retinal parts, the fluorescein 
angiography was delayed until the bleeding cleared up.
The surgical technique that yielded the sample collection 
was described in a separate report.12 Briefly, 0.6 to 0.8 mL of 
undiluted vitreous fluid from the mid- to posterior vitreous 
cavity were extracted by an assistant, under the guidance 
of the surgeon who controlled the vitrector (Insight Instru-
ments, Inc. Stuart, FL, USA) with a headset and a magnifying 
28-diopter lens.
Samples  taken  from  an  idiopathic,  nonuveitic 
floaterectomy served as the controls. All samples were saved 
prior to drug application and frozen at −80°C.
The Cytometric Bead Array (CBA) Flex Set System (BD 
Biosciences, Heidelberg, Germany) was used to determine 
the IL-6, MCP-1, and VEGF-A, according to the manufac-
turer’s instruction manual, including the measurement on a 
FACSArray™ Bioanalyzer (BD Biosciences) with FCAP 
Array™ v3.01 software (Soft Flow Hungary Ltd, Pécs, 
Hungary). The data were saved in EXCEL (Microsoft Office 
2010; Microsoft Corp, Redmond, WA, USA) and statistically 
analyzed with BiAS software v8.3.8 (Epsilon, Darmstadt, 
Germany). The data had a nonparametric distribution, which 
was checked with the David’s test (error level of 5%); thus 
the Wilcoxon–Mann–Whitney test could be applied with a 
P-value of ,0.05.
The Spearman rank correlation coefficient was used 
to examine the relationship between the influence of the 
cytokines on the other parameters, such as changes in 
SD-OCT.
Results
Patients
The BRVO group (23 men and 20 women) was aged 
69.7 ± 12.9 years (mean ± standard deviation [SD]), and 
the control group (12 men and 16 women) was aged 
66.2 ± 7.9 years (P = 0.91 and 0.32, respectively) (Table 1). 
TRT TNeuro
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Figure 1 Cystoid macular edema secondary to a “fresh” BRVO, with marked TRT, Tneuro, and SRT, as seen in SD-OCT.
Note: Thickness was measured in µm.
Abbreviations: BRVO, branch retinal vein occlusion; SD-OCT, spectral-domain optical coherence tomography; SRT, subfoveal serous retinal thickness; Tneuro, thickness 
of the neurosensory retina; TRT, total retinal thickness.
Table 1 Epidemiological data
BRVO 
N = 43
Control P-value
43 28
Male/female 23/20 12/16 0.91
Age in years 69.7 ± 12.9 66.2 ± 7.9 0.32
Blood pressure*
  Systolic 144 ± 17 121 ± 10 ,0.01
  Diastolic 82 ± 17 75 ± 8 0.08
Hypertension 33 5 ,0.001
Drug therapy 21 3 0.004
VA in logMAR 0.85 ± 0.51 0.51 ± 0.22 ,0.002
Duration of BRVO** 6.7 ± 4.0
Type Fresh Older
BRVO
 n 28 15 ,0.01
  Duration of BRVO 4.1 ± 1.5 11.6 ± 1.7 ,0.001
Notes:  Values  are  expressed  as  mean  (±standard  deviation).  Differences  are 
calculated using the Wilcoxon–Mann–Whitney test. *mmHg; **months.
Abbreviations: BRVO, branch retinal vein occlusion; logMAR, logarithm of the 
minimum angle of resolution; VA, visual acuity.
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Table 2 Characteristics of the SD-OCT measurements
All Control P-value Fresh Older P-value
BRVO cytokines
IL-6 23.2 ± 48.8 
(8.2–38.2)
6.2 ± 3.4 
(4.9–7.5)
0.17 28.2 ± 59.3 
(5.2–51.2)
13.8 ± 148 
(5.7–22.1)
0.23
MCP-1 602.6 ± 490.3 
(451.7–753.5)
253 ± 74 
(225–282)
0.001 633.7 ± 567.5 
(413.7–853.7)
544.4 ± 307.2 
(374.3–714.5)
0.51
VEGF-A 161.8 ± 314.3 
(65.1–258.6)
7 ± 4.9 
(5.1–8.9)
0.003 190.9 ± 365.3 
(49.2–332.5)
107.6 ± 184.9 
(5.2–209.9)
0.33
BRVO 
SD-OCT
All 
N = 43
Fresh 
N = 28
Older 
N = 15
P-value
CMT 459.5 ± 144.1 
(415.1–504.4)
450.9 ± 160.1 
(388.8–512.9)
475.6 ± 111.6 
(413.8–537.4)
0.34
TRT 531.9 ± 170.6 
(479.1–584.3)
509 ± 189.4 
(435.6–583)
574.4 ± 122.9 
(506.3–642.5)
0.18
Tneuro 430.9 ± 101.6 
(399.6–462.2)
425.2 ± 99.2 
(386.7–463.7)
441 ± 108.7 
(381–501.5)
0.85
SRT 116.3 ± 140 
(73.2–159.4)
136.4 ± 158.7 
(74.8–197.9)
78.8 ± 89 
(29.5–128.1)
0.31
dEL 2487.4 ± 1385.7 
(2061–2914)
2383 ± 1397 
(1841–2924)
2683 ± 1392 
(1913–3453)
0.72
dELM 2892.6 ± 1391.9 
(2464–3321)
2774 ± 1474 
(2202–3345)
3115 ± 1241 
(2428–3802)
0.69
Cysts 40 26 14 0.98
HR-Spots 8 3 5 0.24
Notes: The absolute mean values of the vitreous cytokines are in pg/mL. All measurements are depicted as mean values ± SD in µm. The 95% confidence interval values 
are depicted in brackets.
Abbreviations: BRVO, branch retinal vein occlusion; CMT, central macular thickness; Cysts, intraretinal cysts; dEL, disruption of the inner and outer photoreceptor 
segments;  dELM,  disruption  of  the  external  limiting  membrane;  HR-spots,  hyperreflective  spots;  IL-6,  interleukin-6;  MCP-1,  monocyte  chemoattractant  protein-1; 
SD, standard deviation; SD-OCT, spectral-domain optical coherence tomography; SRT, subfoveal serous retinal thickness; Tneuro, thickness of the neurosensory retina; 
TRT, total retinal thickness; VEGF-A, vascular endothelial growth factor-A.
The VA was 0.85 ± 0.51 logMAR in the BRVO group and 
0.51 ± 0.22 in the control group (P , 0.002). The duration of 
the BRVO was 6.7 ± 4.0 months for all BRVO patients, and 
all were treatment naïve before the study start. The patients 
were distributed in a subgroup of fresh BRVO with a duration 
of 4.1 ± 1.5 months (n = 28) and a subgroup of old BRVO 
with a duration of 11.6 ± 1.7 months after the onset of the 
disease (P , 0.001), which was classified based upon the 
patients’ subjective perception of symptoms. We defined a 
fresh BRVO as having a duration of less than 6 months.
SD-OCT
The mean absolute values ± SD and the 95% confidence 
interval (CI) of the SD-OCT measurements are depicted 
in µm in Table 2. For all BRVO patients, the mean 
CMT was 459.5 ± 144.1 (CI 415.1–504.4 µm), the TRT 
was 531.9 ± 170.6 (CI 479.1–584.3), the TNeuro was 
430.9 ± 101.6 (CI 399.6–462.2), the SRT was 116.3 ± 140 (CI 
73.2–159.4), the dEL was 2487.4 ± 1385.7 (CI 2061–2914), 
and the dELM was 2892.6 ± 1391.9 (CI 2464–3321). In 
40 out of 43 patients (93%), intraretinal cysts were noted, 
while in eight out of 43 patients (19%), hyper-reflective spots 
occurred. For the subgroup with older BRVO, higher values 
were observed for all SD-OCT parameters aside from SRT 
in comparison with the fresh BRVO subgroup.
Correlation of SD-OCT
The CMT correlated significantly with TRT (r = 0.83), with 
SRT (r = 0.58), with dEL (r = 0.58), with dELM (r = 0.48), 
and with intraretinal cysts (r = 0.36). TRT correlated 
significantly with TNeuro (r = 0.42), with SRT (r = 0.61), 
with dEL (r = 0.71), and with dELM (r = 0.64), and with 
intraretinal cysts (r = 0.35). TNeuro and SRT correlated 
significantly with dEL (r = 0.39 and 0.66, respectively), 
with dELM (r = 0.40 and 0.59, respectively), and with 
intraretinal cysts (r = 0.42 and 0.30, respectively). dEL and 
dELM correlated significantly with one another (r = 0.90). 
In total, TRT correlated with six; CMT, SRT, dEL, and 
dELM correlated with five; and TNeuro and intraretinal cysts 
correlated with four SD-OCT parameters.
In the fresh BRVO group, there were more significant 
correlations among the SD-OCT parameters than were in 
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the older BRVO group (15 versus five) (Table 3). In the fresh 
group, CMT correlated significantly with TRT (r = 0.79), 
with SRT (r = 0.65), and with dEL (r = 0.68) and with dELM 
(r = 0.57). TRT correlated significantly with SRT (r = 0.63), 
with dEL (r = 0.77), and with dELM (r = 0.71). TNeuro 
and SRT correlated significantly with dEL (0.48 and 0.68, 
respectively), with dELM (r = 0.47 and 0.64, respectively), 
and TNeuro, was also correlated significantly with cysts 
(r = 0.43). dEL and dELM correlated significantly with 
one another (r = 0.90). Intraretinal cysts correlated with 
dEL and dELM (both had r = 43). In total, dEL and dELM 
correlated with six; CMT and TRT correlated with four; and 
TNeuro, SRT, and intraretinal cysts correlated with three 
SD-OCT parameters. In the old BRVO group, TRT correlated 
with CMT and TRT (r = 0.81 and 0.76, respectively), and 
SRT correlated with CMT and dEL (r = 0.66 and 0.52, 
respectively). dEL and d/ELM correlated with r = 0.91.
Vitreal cytokine levels
The mean vitreal IL-6, MCP-1, and VEGF-A levels can be 
found in Table 2.
Correlation between cytokines
All cytokines were positively correlated with one another. 
IL-6 was positively correlated (Table 4) with both MCP-1 
(r = 0.79; P , 0.0001) and VEGF-A (r = 0.46; P , 0.0001); 
MCP-1 was correlated with VEGF-A (r = 0.42; P , 0.0001). 
This was also true in the fresh versus older BRVO subgroup 
analysis (Table 3), where the IL-6 level was correlated with 
MCP-1 (r = 0.77; P , 0.0001) and VEGF-A (r = 0.68; 
P , 0.0001). MCP-1 levels were correlated with VEGF-A 
(r = 0.68; P , 0.006) in the older BRVO subgroup. In the 
fresh BRVO subgroup, there was a significant correlation 
among the inflammatory cytokines, IL-6 with MCP-1 
(r = 0.80; P , 0.001).
Correlation of cytokines and VA 
with SD-OCT
VEGF-A was the only cytokine to correlate significantly with 
the SD-OCT parameters. It correlated with TNeuro (r = 0.31, 
P , 0.04) and with dEL (r = 0.33, P , 0.03). In the subgroup 
analysis, there was a correlation seen in only the fresh BRVO 
group, where VEGF correlated significantly with TNeuro 
Table 3   Spearman  rank  correlation  matrix  presenting  the  fresh  BRVO  subgroup  (no  shading)  and  the  old  BRVO  subgroup 
(grey shading)
Fresh/ 
old
VA CMT TRT TNeuro SRT dEL dELM Cysts IL-6 MCP-1 VEGF-A
VA 0.30 
(0.12)
0.25 
(0.19)
0.28 
(0.14)
0.49* 
(0.01)
0.32 
(0.10)
0.29 
(0.13)
0.25 
(0.21)
0.33 
(0.10)
0.25 
(0.21)
0.53* 
(0.004)
CMT 0.26 
(0.37)
0.79* 
(0.001)
0.15 
(0.47)
0.65* 
(0.001)
0.68* 
(0.001)
0.57* 
(0.002)
0.33 
(0.10)
0.07 
(0.73)
−0.04 
(0.88)
0.24 
(0.23)
TRT 0.40 
(0.1)
0.81* 
(0.001)
0.38 
(0.05)
0.63* 
(0.001)
0.77* 
(0.001)
0.71* 
(0.001)
0.37 
(0.06)
0.04 
(0.87)
−0.06 
(0.75)
0.33 
(0.09)
Tneuro 0.34 
(0.21)
0.40 
(0.15)
0.48 
(0.07)
0.13 
(0.49)
0.48* 
(0.02)
0.47* 
(0.01)
0.43* 
(0.03)
−0.02 
(0.91)
0.24 
(0.23)
0.37* 
(0.05)
SRT 0.35 
(0.2)
0.66* 
(0.01)
0.76* 
(0.001)
0.21 
(0.44)
0.68* 
(0.001)
0.64* 
(0.001)
0.32 
(0.10)
0.04 
(0.58)
−0.15 
(0.44)
0.23 
(0.25)
dEL 0.24 
(0.40)
0.28 
(0.32)
0.50 
(0.06)
0.19 
(0.51)
0.52* 
(0.05)
0.90* 
(0.001)
0.43* 
(0.02)
0.07 
(0.71)
0.04 
(0.84)
0.34 
(0.08)
dELM 0.40 
(0.15)
0.24 
(0.38)
0.42 
(0.13)
0.09 
(0.76)
0.50 
(0.56)
0.91* 
(0.001)
0.43* 
(0.02)
−0.03 
(0.90)
−0.07 
(0.72)
0.29 
(0.14)
Cysts 0.45 
(0.09)
0.43 
(0.11)
0.43 
(0.11)
0.44 
(0.11)
0.26 
(0.35)
−0.25 
(0.37)
−0.37 
(0.17)
−0.01 
(0.97)
0.07 
(0.23)
0.10 
(0.63)
IL-6 0.36 
(0.19)
−0.01 
(0.98)
0.07 
(0.83)
0.38 
(0.16)
−0.29 
(0.30)
0.32 
(0.26)
0.27 
(0.35)
0.06 
(0.83)
0.80* 
(0.001)
0.33 
(0.09)
MCP-1 0.28 
(0.32)
−0.27 
(0.32)
−0.17 
(0.55)
0.23 
(0.42)
−0.36 
(0.19)
0.03 
(0.92)
0.01 
(0.96)
0.19 
(0.51)
0.77* 
(0.001)
0.32 
(0.10)
VEGF-A 0.23 
(0.42)
0.18 
(0.52)
0.20 
(0.48)
0.23 
(0.41)
−0.04 
(0.88)
0.34 
(0.22)
0.21 
(0.46)
0.31 
(0.25)
0.68* 
(0.01)
0.68* 
(0.006)
Notes: Objective VA (logMAR) and SD-OCT values are correlated among each other and with the values of the vitreal cytokines. The results are represented with 
correlation coefficient r and P-values in brackets; *statistically significant correlations.
Abbreviations: BRVO, branch retinal vein occlusion; CMT, central macular thickness; Cysts, intraretinal cysts; dEL, disruption of the inner and outer photoreceptor 
segments; dELM, disruption of the external limiting membrane; IL-6, interleukin-6; logMAR, logarithm of the minimum angle of resolution; MCP-1, monocyte chemoattractant 
protein-1; SD-OCT, spectral-domain optical coherence tomography; SRT, subfoveal serous retinal thickness; TRT, total retinal thickness; Tneuro, thickness of the 
neurosensory retina; VA, visual acuity; VEGF-A; vascular endothelial growth factor-A.
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Table 4 Spearman rank correlation matrix
VA CMT TRT TNeuro SRT dEL dELM Cysts IL-6 MCP-1 VEGF-A
VA 0.34* 
(0.02)
0.34* 
(0.03)
0.34* 
(0.03)
0.48* 
(0.002)
0.33* 
(0.03)
0.37* 
(0.02)
0.30* 
(0.04)
0.31 
(0.45)
0.22 
(0.18)
0.42* 
(0.01)
CMT 0.83* 
(0.001)
0.24 
(0.12)
0.58* 
(0.001)
0.58* 
(0.001)
0.48* 
(0.001)
0.36* 
(0.02)
0.04 
(0.82)
–0.09 
(0.55)
0.20 
(0.2)
TRT 0.42* 
(0.005)
0.61* 
(0.001)
0.71* 
(0.001)
0.64* 
(0.001)
0.35* 
(0.02)
0.05 
(0.78)
–0.06 
(0.70)
0.27 
(0.09)
Tneuro 0.18 
(0.24)
0.39* 
(0.01)
0.40* 
(0.01)
0.42* 
(0.001)
0.14 
(0.38)
0.22 
(0.16)
0.31* 
(0.04)
SRT 0.66* 
(0.001)
0.59* 
(0.001)
0.30* 
(0.04)
–0.003 
(0.85)
–0.19 
(0.22)
0.18 
(0.25)
dEL 0.90* 
(0.001)
0.23 
(0.14)
0.13 
(0.42)
0.02 
(0.93)
0.33* 
(0.03)
dELM 0.19 
(0.23)
0.07 
(0.68)
–0.05 
(0.73)
0.30 
(0.06)
Cysts 0.05 
(0.76)
0.09 
(0.61)
0.17 
(0.29)
IL-6 0.79* 
(0.001)
0.46* 
(0.001)
MCP-1 0.42* 
(0.001)
VEGF-A
Notes: Objective VA (logMAR) and SD-OCT values are correlated among each other and with the values of the vitreal cytokines (IL-6, MCP-1, and VEGF-A). The results 
are represented with the correlation coefficient r and P-values are in brackets; *statistically significant correlations.
Abbreviations: CMT, central macular thickness; Cysts, intraretinal cysts; dEL, disruption of the inner and outer photoreceptor segments; dELM, disruption of the external 
limiting membrane; IL-6, interleukin-6; logMAR, logarithm of the minimum angle of resolution; MCP-1, monocyte chemoattractant protein-1; SD-OCT, spectral-domain 
optical coherence tomography; SRT, subfoveal serous retinal thickness; TRT, total retinal thickness; Tneuro, thickness of the neurosensory retina; VA, visual acuity; VEGF-A; 
vascular endothelial growth factor-A.
(r = 0.37, P , 0.05). VA was analyzed with logMAR values and 
correlated significantly to all SD-OCT parameters (Table 4). VA 
and CMT (r = 0.34), TRT (r = 0.34), TNeuro (r = 0.34), SRT 
(r = 0.48), dEL (r = 0.33), dELM (r = 0.37), and intraretinal cysts 
(r = 0.30) were all correlated. VEGF was the only cytokine that 
correlated with VA significantly (r = 0.42), and this was also 
demonstrated in the fresh BRVO subgroup (r = 0.53).
Discussion
Early intravitreal injections after the onset of BRVO and 
intact retinal layers (like ELM), as assessed by SD-OCT, are 
associated with a better visual outcome.13,14 In this study, we 
assessed the levels of inflammatory and angiogenic cytokines 
in the undiluted vitreous of treatment-naïve patients with ME 
secondary to nonischemic BRVO using flow cytometric BEAD 
array, and we correlated the results with objective clinical 
parameters, such as BRVO-associated changes in SD-OCT.
Recent studies with SD-OCT have shown that ME 
secondary to BRVO is often characterized by numerous 
cystoid spaces and marked retinal swelling, especially in the 
outer retinal layers.15,16 We are not aware of any correlation 
of SD-OCT parameters with intraocular cytokine levels 
published to date. In our study, VEGF-A was the only cytokine 
to positively correlate significantly with two SD-OCT 
parameters (TNeuro and dEL). Tsujikawa et al3 previously 
described the importance of the integrity of the EL as a 
landmark for good VA. Interestingly, we could demonstrate 
that elevated VEGF was associated with the disruption 
of the EL junction and the thickness of the neurosensory 
retina. VEGF was the only cytokine that also correlated with 
VA. As this finding was pronounced in the fresh BRVO 
subgroup, we speculate that the ME in the acute phase may 
be predominated by the barrier breakdown of the vascular 
wall, caused by VEGF. We demonstrated higher levels for all 
three cytokines in the fresh BRVO subgroup compared with 
the old BRVO subgroup. Although MCP-1 induces VEGF-A 
gene expression by upregulating hypoxia-inducible factor 1 
(HIF-1 alpha), we could not determine high cytokine levels 
in the older BRVO subgroup.17,18 Thus, it seems that VEGF 
and MCP-1 are not the key cytokines during the chronic 
stage in older BRVO cases and that other cytokines are more 
appropriately examined in these cases.
Funk et al5 examined aqueous samples with CBA at 
baseline prior to intravitreal anti-VEGF therapy in eight 
patients, 10 months after the onset of nonischemic BRVO. 
The IL-6 (∆ = −2 pg/mL), MCP-1 (∆ = −83 pg/mL), and 
VEGF levels (∆ = −40 pg/mL) were all lower than in our 
study. However, it is questionable whether the aqueous 
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samples and low number of patients can be compared with 
our study results in BRVO, as we strive to understand more 
about this original retinal disease.
The limitations of our study are the small sample size, 
which may have to be taken into consideration, especially 
when interpreting the ischemic BRVO group significant 
differences.
The concept of our study was to provide evidence about 
cytokines and their correlation to SD-OCT changes in the 
undiluted vitreous of patients suffering from a condition 
other than vitreomacular traction or other clinical state that 
would have qualified for a complete three-port vitrectomy 
(as in the studies by Noma et al).10,15,16
In conclusion, we demonstrated significantly higher values 
of inflammatory and proangiogenic cytokines in eyes with 
“fresh,” treatment-naïve BRVO compared with control eyes. 
The cytokines highly correlated with one another. VEGF-A 
was partly correlated with the morphologic changes assessed 
by SD-OCT, whereas the inflammatory markers had no 
significant influence on SD-OCT changes. The morphological 
changes detected in SD-OCT may in the future, become more 
clinically relevant with a direct biofeedback mechanism, like 
the vitreal load of dysregulated cytokines.
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